Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma.
暂无分享，去创建一个
P. Hari | R. Orentas | A. Worden | D. Schneider | B. Dropulić | N. Shah | M. Hamadani | T. Fenske | W. Krueger | F. Zhu | W. Longo | Carolyn Taylor | Bryon D. Johnson